Paul A. LaViolette is a seasoned executive in the medical device and healthcare industries, currently serving as the Chief Executive Officer and Co-Chairman of Pulse Biosciences Inc., a pioneering company focused on developing innovative bioelectric medicine technologies. With over four decades of experience, LaViolette has built a reputation for driving growth and innovation in high-stakes environments. He joined Pulse Biosciences in 2023, bringing his extensive expertise to lead the company's strategic direction, particularly in advancing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for applications in cardiology, oncology, and other therapeutic areas. Under his leadership, Pulse Biosciences aims to revolutionize non-thermal tissue ablation, offering safer and more effective alternatives to traditional surgical methods. Prior to his role at Pulse Biosciences, LaViolette held prominent positions at leading healthcare firms, including serving as Managing Partner and Operating Advisor at SV Health Investors, where he specialized in medtech investments and operational guidance. He is perhaps best known for his transformative tenure at Boston Scientific Corporation, where he rose to the position of Senior Vice President and Group President of Cardiovascular Businesses, overseeing a portfolio that generated billions in revenue and spearheaded groundbreaking advancements in interventional cardiology and electrophysiology. His achievements include orchestrating major acquisitions, expanding global market presence, and fostering R&D initiatives that resulted in numerous FDA approvals and patented technologies, significantly impacting patient outcomes worldwide. In his current capacity at Pulse Biosciences, LaViolette is instrumental in navigating regulatory pathways, securing funding, and building strategic partnerships to accelerate the commercialization of nsPFA platforms. His visionary approach has already contributed to key milestones, such as clinical trial progress and enhanced investor confidence. LaViolette's commitment to innovation is further evidenced by his board roles at various medtech companies and his recognition as a thought leader in healthcare transformation, earning accolades from industry associations for his contributions to medical advancements.